BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ladetto M, Ferrero S, Drandi D, Festuccia M, Patriarca F, Mordini N, Cena S, Benedetto R, Guarona G, Ferrando F, Brunello L, Ghione P, Boccasavia V, Fanin R, Omedè P, Giaccone L, Palumbo A, Passera R, Boccadoro M, Bruno B. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. Leukemia 2016;30:1211-4. [DOI: 10.1038/leu.2015.269] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Bladé J, Bruno B, Mohty M. Multiple Myeloma. In: Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT Handbook. Cham: Springer International Publishing; 2019. pp. 603-7. [DOI: 10.1007/978-3-030-02278-5_80] [Reference Citation Analysis]
2 Bai Y, Orfao A, Chim CS. Molecular detection of minimal residual disease in multiple myeloma. Br J Haematol. 2018;181:11-26. [PMID: 29265356 DOI: 10.1111/bjh.15075] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
3 Ladetto M, Böttcher S, Kröger N, Pulsipher MA, Bader P. Methods and role of minimal residual disease after stem cell transplantation. Bone Marrow Transplant 2019;54:681-90. [PMID: 30116018 DOI: 10.1038/s41409-018-0307-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Nair AP, Walker P, Kalff A, Bergin K, Hocking J, Avery S, Curtis DJ, Patil S, Das T, Klarica D, Morgan S, Muirhead J, Gorniak M, Reynolds J, Spencer A. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma. Bone Marrow Transplant 2017;52:839-45. [DOI: 10.1038/bmt.2017.37] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
5 Drandi D, Ferrero S, Ladetto M. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders. In: Karlin-neumann G, Bizouarn F, editors. Digital PCR. New York: Springer; 2018. pp. 229-56. [DOI: 10.1007/978-1-4939-7778-9_14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
6 Serrano-Del Valle A, Anel A, Naval J, Marzo I. Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Front Cell Dev Biol 2019;7:50. [PMID: 31041312 DOI: 10.3389/fcell.2019.00050] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 18.0] [Reference Citation Analysis]
7 Avet-Loiseau H, Ludwig H, Landgren O, Paiva B, Morris C, Yang H, Zhou K, Ro S, Mateos MV. Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis. Clin Lymphoma Myeloma Leuk 2020;20:e30-7. [PMID: 31780415 DOI: 10.1016/j.clml.2019.09.622] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
8 Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125:3059-3068. [PMID: 25838346 DOI: 10.1182/blood-2014-11-568907] [Cited by in Crossref: 178] [Cited by in F6Publishing: 166] [Article Influence: 25.4] [Reference Citation Analysis]
9 Green DJ, Bensinger WI. A View from the Plateau: Is There a Role for Allogeneic Stem Cell Transplantation in the Era of Highly Effective Therapies for Multiple Myeloma? Curr Hematol Malig Rep 2017;12:61-7. [PMID: 28144893 DOI: 10.1007/s11899-017-0365-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chen Y, Fu WJ, Xu LP, Ren HY, Lai YR, Liu DH, Liu L, Sun ZM, Wu YB, Wang X, Xia LH, Jiang M, Hu TL, Wan DM, Huang XJ. Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma. Chin Med J (Engl) 2019;132:1765-72. [PMID: 31306219 DOI: 10.1097/CM9.0000000000000341] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Bruno B, Auner HW, Gahrton G, Garderet L, Festuccia M, Ladetto M, Lemoli RM, Massaia M, Morris C, Palumbo A, Schönland S, Boccadoro M, Kröger N. Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting). Leuk Lymphoma 2016;57:1256-68. [PMID: 26735310 DOI: 10.3109/10428194.2015.1131278] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
12 Müller AMS, Kumar SK, Bruno B. The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all? Haematologica 2019;104:222-5. [PMID: 30705115 DOI: 10.3324/haematol.2018.206987] [Reference Citation Analysis]
13 Kumar S, Glazebrook KN, Broski SM. Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma. PET Clin 2019;14:391-403. [PMID: 31084778 DOI: 10.1016/j.cpet.2019.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Brunetti C, Anelli L, Zagaria A, Minervini A, Minervini CF, Casieri P, Coccaro N, Cumbo C, Tota G, Impera L, Orsini P, Specchia G, Albano F. Droplet Digital PCR Is a Reliable Tool for Monitoring Minimal Residual Disease in Acute Promyelocytic Leukemia. The Journal of Molecular Diagnostics 2017;19:437-44. [DOI: 10.1016/j.jmoldx.2017.01.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
15 Kostopoulos IV, Ntanasis-Stathopoulos I, Gavriatopoulou M, Tsitsilonis OE, Terpos E. Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. Front Oncol 2020;10:860. [PMID: 32537439 DOI: 10.3389/fonc.2020.00860] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
16 Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, Petersen E, Schaap N, Bonifazi F, Volin L, Meijer E, Niederwieser D, El-cheikh J, Tabrizi R, Fegeux N, Finke J, Bunjes D, Cornelissen J, Einsele H, Bruno B, Potter M, Fanin R, Mohty M, Garderet L, Kröger N. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia 2016;30:2047-54. [DOI: 10.1038/leu.2016.101] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
17 Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, Dimopoulos M, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica 2018;103:197-211. [PMID: 29217780 DOI: 10.3324/haematol.2017.174573] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 15.6] [Reference Citation Analysis]
18 Giaccone L, Evangelista A, Patriarca F, Sorasio R, Pini M, Carnevale-Schianca F, Festuccia M, Brunello L, Zallio F, Maffini E, Omedé P, Bringhen S, Mordini N, Fanin R, Ciccone G, Boccadoro M, Bruno B. Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma. Biol Blood Marrow Transplant 2018;24:189-93. [PMID: 28987930 DOI: 10.1016/j.bbmt.2017.09.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
19 Rodríguez-Otero P, Paiva B, Engelhardt M, Prósper F, San Miguel JF. Is immunotherapy here to stay in multiple myeloma? Haematologica 2017;102:423-32. [PMID: 28082344 DOI: 10.3324/haematol.2016.152504] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
20 Mosebach J, Shah S, Delorme S, Hielscher T, Goldschmidt H, Schlemmer HP, Schönland S, Hegenbart U, Hillengass J. Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation. Haematologica 2018;103:336-43. [PMID: 29217779 DOI: 10.3324/haematol.2017.176073] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Bolli N, Genuardi E, Ziccheddu B, Martello M, Oliva S, Terragna C. Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time? Front Oncol 2020;10:189. [PMID: 32181154 DOI: 10.3389/fonc.2020.00189] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
22 Bruno B. Allogeneic transplantation for multiple myeloma: yes, no or maybe? Bone Marrow Transplant 2016;51:506-7. [PMID: 26901704 DOI: 10.1038/bmt.2016.12] [Reference Citation Analysis]
23 Coccaro N, Anelli L, Zagaria A, Casieri P, Tota G, Orsini P, Impera L, Minervini A, Minervini CF, Cumbo C, Parciante E, Carluccio P, Brunetti C, Specchia G, Albano F. Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia. The Journal of Molecular Diagnostics 2018;20:474-82. [DOI: 10.1016/j.jmoldx.2018.03.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
24 Martino M, Paviglianiti A, Gentile M, Martinelli G, Cerchione C. Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking? Panminerva Med 2020;62:234-43. [PMID: 32955185 DOI: 10.23736/S0031-0808.20.04142-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Bai Y, Chim CS. Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma. Hematology 2019;24:533-7. [PMID: 31280705 DOI: 10.1080/16078454.2019.1637574] [Reference Citation Analysis]
26 Fernández de Larrea C, Dávila J, Isola I, Ocio EM, Rosiñol L, García-Sanz R, Cibeira MT, Tovar N, Rovira M, Mateos MV, Miguel JS, Bladé J. Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2017;52:567-9. [PMID: 27869809 DOI: 10.1038/bmt.2016.299] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
27 Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, Chauncey TR, Hari P, Lange T, Pulsipher MA, McSweeney PA, Holmberg L, Becker PS, Green DJ, Mielcarek M, Maloney DG, Storb R. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica 2019;104:380-91. [PMID: 30262560 DOI: 10.3324/haematol.2018.200253] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
28 Costa LJ, Iacobelli S, Pasquini MC, Modi R, Giaccone L, Blade J, Schonland S, Evangelista A, Perez-Simon JA, Hari P, Brown EE, Giralt SA, Patriarca F, Stadtmauer EA, Rosinol L, Krishnan AY, Gahrton G, Bruno B. Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. Bone Marrow Transplant 2020;55:1810-6. [PMID: 32286506 DOI: 10.1038/s41409-020-0887-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]